Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|July 20, 2020

BioPharm International Editorial Advisory Board

The BioPharm International Editorial Advisory Board shares their professional expertise in bioprocessing topics to help shape editorial content and review peer-review papers.

The following biopharma industry experts serve as members of the BioPharm International Editorial Advisory Board.

  • K. A. Ajit-Simh, President, Shiba Associates
  • Madhavan Buddha, Freelance Consultant
  • Rory Budihandojo, Independent Consultant
  • Suggy S. Chrai, President and CEO, The Chrai Associates
  • Uwe Gottschalk, Vice-President, Chief Technology Officer, Pharma/Biotech, Lonza AG
  • Fiona M. Greer, Senior Consultant, BioPharmaSpec (UK)
  • Rajesh K. Gupta, Vaccinnologist and Microbiologist
  • Denny Kraichely, Department Head, Analytical Project Leadership, Merck Vaccines
  • Stephan O. Krause, Head of Product Quality Group, AstraZeneca Biologics
  • Steven S. Kuwahara, Principal Consultant, GXP BioTechnology LLC
  • Eric S. Langer, President and Managing Partner, BioPlan Associates, Inc.
  • Howard L. Levine, Senior Managing Director, BDO, National Leader, BioProcess Technology Group
  • Hank Liu, Head of Quality Control, Sanofi Pasteur
  • Herb Lutz, Principal Consulting Engineer, Merck Millipore
  • Hanns-Christian Mahler, Head Drug Product Services, Lonza AG
  • Jerold Martin, Independent Consultant
  • Hans-Peter Meyer, Lecturer, University of Applied Sciences and Arts Western Switzerland, Institute of Life Technologies
  • K. John Morrow, President, Newport Biotech
  • David Radspinner, VP/GM Global Commercial Transition, Cytiva
  • Tom Ransohoff, COO, 4th Dimension Bioprocess
  • Anurag Rathore, Biotech CMC Consultant, Faculty Member, Indian Institute of
    Technology
  • Susan J. Schniepp, Executive Vice President of Post-Approval Pharma and Distinguished Fellow, Regulatory Compliance Associates, Inc.
  • Tim Schofield, Consultant, CMC Sciences, LLC
  • Paula Shadle, Principal Consultant, Shadle Consulting
  • Thomas J. Vanden Boom, Independent Biotechnology Consultant
  • Steven Walfish, Principal Scientific Liaison, USP

Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.